By Susan Heavey WASHINGTON (Reuters) - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus. "Their lives, in short, will be transformed," Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani said at the group's annual meeting in Washington. "The value to these patients, and to their loved ones and society - you can't put a price tag on it." Gilead's Sovaldi costs about $84,000 for a 12-week course of treatment, or $1,000 a day. This week, the World Health Organization joined the chorus of those seeking affordability for such drugs. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment